FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors
- DOI
- 10.1016/j.jtha.2026.09.004
- Published
- 2026-09
- Container
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtha.2026.09.004,
title = {FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors},
author = {Cédric Hermans and Gary Benson and Davide Matino and Keiji Nogami and Johannes Oldenburg and Flora Peyvandi and Michele Schiavulli and Allison P. Wheeler and Julien Bovet and Amalie Roar Høgh and Robert Klamroth},
year = {2026},
journal = {Journal of Thrombosis and Haemostasis},
doi = {10.1016/j.jtha.2026.09.004},
url = {https://doi.org/10.1016/j.jtha.2026.09.004}
}RIS
TY - JOUR TI - FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors AU - Cédric Hermans AU - Gary Benson AU - Davide Matino AU - Keiji Nogami AU - Johannes Oldenburg AU - Flora Peyvandi AU - Michele Schiavulli AU - Allison P. Wheeler AU - Julien Bovet AU - Amalie Roar Høgh AU - Robert Klamroth PY - 2026 JO - Journal of Thrombosis and Haemostasis DO - 10.1016/j.jtha.2026.09.004 UR - https://doi.org/10.1016/j.jtha.2026.09.004 ER -
APA
Hermans, C., Benson, G., Matino, D., Nogami, K., Oldenburg, J., Peyvandi, F., Schiavulli, M., Wheeler, A. P., Bovet, J., Høgh, A. R., & Klamroth, R. (2026). FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.09.004
Source records
- crossref · retrieved 2026-09-26T20:32:05.746Z